Encelle Inc. of Raleigh, an emerging biomaterials company, has received a $100,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to evaluate the company's proprietary hydrogel matrix, an injectable biopolymer material that has shown initial promise in wound healing.
"Encelle is developing wound-healing and other applications of its unique biomaterials technology," said James D. Woodward, Encelle's CEO. "This technology, originally discovered in the company's development of a bioartificial pancreas, is now the central focus of our development efforts."
Encelle recently filed an Investigational Device Exemption …
No comments:
Post a Comment